【文/观察者网 张菁娟】据香港英文媒体《南华早报》12日报道，在美工作30年后，全球顶尖计算生物 学家鲍志戎选择回国，全职加盟深圳南方科技大学，担任讲席教授。 根据南方科技大学生命科学学院最新公布的教师简介，鲍志戎毕业于吉林大学（学士、硕士）及圣路易 华盛顿大学（博士），并先后在华盛顿大学（西雅图）从事博士后研究及纪念斯隆凯特林癌症中心任助 教授至正教授。 报道称，他是成像技术领域的开拓者，其团队研发的技术，可让科学家实时追踪器官形成与疾病发生过 程中单个细胞的活动轨迹。 在美期间，鲍志戎曾主持由美国国立卫生研究院（NIH）资助的数百万美元科研项目。在斯隆凯特林癌 症中心，他带领团队开发出先进成像技术，能以每分钟一次的频率，捕捉线虫胚胎发育全过程的高分辨 率三维图像，精准追踪每一个细胞的分裂、迁移及基因开闭状态。 秀丽隐杆线虫仅有约300个神经元，极大简化了神经系统研究，是生命发育研究的经典模式生物，但肌 肉形成后的胚胎活体观测一直是困扰全球科研界的难题。 这套高频成像技术所捕捉的"发育影像"，让鲍志戎团队得以重构器官从零开始的形成过程，为解析正常 发育机制、揭示癌症等疾病中发育过程的异常畸变，提供了详尽的分 ...

Core Insights - AlphaFold2, developed by Google DeepMind, has revolutionized scientific research by enabling accurate predictions of protein structures based solely on amino acid sequences since its launch in November 2020 [1][4][7]. Group 1: Impact on Scientific Research - Over the past five years, AlphaFold2 has assisted researchers worldwide in predicting millions of protein structures, marking a second renaissance in structural biology [7]. - The tool has significantly accelerated discovery processes, with researchers like Andrea Pauli stating that every project now utilizes AlphaFold [12]. - The Nature paper describing AlphaFold2 has garnered nearly 40,000 citations, indicating sustained interest from the scientific community [12]. Group 2: Applications and Discoveries - AlphaFold-Multimer, an extension of AlphaFold2, has enabled the discovery of three critical proteins involved in fertilization, challenging previous assumptions about the simplicity of sperm-egg interactions [8][10]. - The TMEM81-IZUMO1-SPACA6 protein complex plays a vital role in mediating sperm-egg binding, highlighting the complexity of fertilization mechanisms [10]. Group 3: User Engagement and Accessibility - AlphaFold has been accessed by approximately 3.3 million users across over 190 countries, with more than 1 million users from low- and middle-income countries, showcasing its global reach and accessibility [15]. - The AlphaFold database (AFDB) contains over 240 million predicted protein structures, covering nearly all known proteins on Earth [15]. Group 4: Influence on Structural Biology and Computational Biology - Researchers using AlphaFold have submitted about 50% more protein structures to the Protein Data Bank (PDB) compared to those who did not use the tool [18]. - AlphaFold has opened new research directions in computational biology, including AI-assisted drug discovery and protein design, leading to increased funding and interest in these areas [21]. Group 5: Future Prospects - AlphaFold2 is expected to aid in understanding disease mechanisms and potentially lead to new therapies, with AlphaFold3 anticipated to enhance drug discovery capabilities [24].

Core Insights - Tianyan Pharmaceutical (ADAG) experienced a 10.09% increase in stock price, reaching $2.51 per share, with a total market capitalization of $118 million as of August 22 [1] - The company's total revenue for the year ending December 31, 2024, is projected to be $103,200, a significant decrease of 99.43% year-over-year [1] - The net profit attributable to the parent company is expected to be -$33.4241 million, reflecting a year-over-year decline of 76.41% [1] Company Overview - Tianyan Pharmaceutical is a platform-driven biopharmaceutical company focused on the development of clinical products, particularly in cancer immunotherapy [1] - The company utilizes a combination of computational biology and artificial intelligence to create novel antibodies with high safety and efficacy [1] - The "Dynamic Precision Library" serves as the company's antibody discovery engine, driving the development of its product pipeline aimed at creating globally innovative or best-in-class products [1]

Core Insights - Tianyan Pharmaceutical (ADAG) opened with a 2.55% increase, trading at $2.01 per share, with a total market capitalization of $94.73 million [1] - The company's total revenue for the year ending December 31, 2024, is reported at $103,200, reflecting a year-over-year decrease of 99.43% [1] - The net profit attributable to the parent company is reported at -$33.42 million, a decrease of 76.41% year-over-year [1] Company Overview - Tianyan Pharmaceutical is a platform-driven biopharmaceutical company focused on the development of clinical products, particularly in cancer immunotherapy [1] - The company utilizes a combination of computational biology and artificial intelligence to develop novel antibodies with high safety and efficacy [1] - The "Dynamic Precision Library" serves as the company's antibody discovery engine, driving the development of its product pipeline aimed at creating innovative or best-in-class products globally [1]

Core Viewpoint - Tianyan Pharmaceuticals (ADAG) experienced a significant stock price increase of 11.73%, reaching $2.19 per share, with a total market capitalization of $103 million as of August 20 [1] Financial Performance - As of December 31, 2024, Tianyan Pharmaceuticals reported total revenue of $103,200, a year-over-year decrease of 99.43% [1] - The company recorded a net loss attributable to shareholders of $33.42 million, reflecting a year-over-year decline of 76.41% [1] Company Overview - Tianyan Pharmaceuticals is a clinical-stage biopharmaceutical company listed on NASDAQ under the ticker ADAG, focused on discovering and developing novel cancer immunotherapies based on original antibodies [1] - The company utilizes a powerful platform that combines computational biology and artificial intelligence to develop new antibodies with high safety and efficacy, aiming to benefit more cancer patients [1] - The company's antibody discovery engine, known as the "Dynamic Precision Library," is driving the development of its product pipeline, with the goal of creating potentially innovative or best-in-class products globally [1]

Core Viewpoint - Tianyan Pharmaceuticals (ADAG) has experienced a significant stock price increase of 7.14%, reaching $2.1 per share, with a total market capitalization of approximately $98.98 million as of August 20 [1] Financial Performance - As of December 31, 2024, Tianyan Pharmaceuticals reported total revenue of $103,200, reflecting a year-on-year decrease of 99.43% [1] - The company's net profit attributable to shareholders was -$33.42 million, representing a year-on-year decline of 76.41% [1] Company Overview - Tianyan Pharmaceuticals is a biopharmaceutical company focused on the development of clinical products driven by its proprietary platform, aiming to discover and develop novel cancer immunotherapies based on original antibodies [1] - The company utilizes a powerful platform that combines computational biology and artificial intelligence to create new antibodies with high safety and efficacy, benefiting cancer patients [1] - The company's antibody discovery engine, known as the "Dynamic Precision Library," is advancing the development of its product pipeline, with the goal of creating potentially innovative or best-in-class products globally [1]

Core Viewpoint - Tianyan Pharmaceutical (ADAG) experienced a significant stock price increase of 20.58%, reaching $2.29 per share, with a total market capitalization of $108 million as of August 7 [1] Financial Performance - As of December 31, 2024, Tianyan Pharmaceutical reported total revenue of $103,200, reflecting a year-over-year decrease of 99.43% [1] - The company recorded a net loss attributable to shareholders of $33.4241 million, which is a 76.41% decrease compared to the previous year [1] Company Overview - Tianyan Pharmaceutical is a biopharmaceutical company focused on the development of clinical products driven by its proprietary platform, specializing in innovative cancer immunotherapies based on original antibodies [1] - The company utilizes a powerful platform that combines computational biology and artificial intelligence to develop new antibodies with high safety and efficacy, aiming to provide solutions for cancer patients [1] - The company's antibody discovery engine, known as the "Dynamic Precision Library," is advancing the development of its product pipeline, with the goal of creating potentially innovative or best-in-class products globally [1]

Core Viewpoint - Tianyan Pharmaceuticals (ADAG) experienced a significant stock price increase of 10.05%, reaching $2.09 per share, with a total market capitalization of $98.45 million as of August 6 [1]. Financial Performance - As of December 31, 2024, Tianyan Pharmaceuticals reported total revenue of $103,200, reflecting a year-over-year decrease of 99.43% [1]. - The company's net profit attributable to shareholders was -$33.42 million, representing a year-over-year decline of 76.41% [1]. Company Overview - Tianyan Pharmaceuticals is a biopharmaceutical company listed on NASDAQ under the ticker ADAG, focused on the development of clinical products driven by its proprietary platform [1]. - The company aims to discover and develop novel cancer immunotherapies based on original antibodies, utilizing a powerful platform that combines computational biology and artificial intelligence [1]. - The company's antibody discovery engine, known as the "Dynamic Precision Library," is advancing the development of its product pipeline, with the goal of creating globally innovative or best-in-class products [1].

Core Insights - Tianyan Pharmaceuticals (ADAG) experienced a 5.03% increase in stock price, reaching $2.09 per share, with a total market capitalization of $98.45 million as of July 30 [1] - The company's total revenue for the year ending December 31, 2024, is projected to be $103,200, reflecting a significant year-over-year decrease of 99.43% [1] - The net profit attributable to the parent company is expected to be -$33.42 million, a decline of 76.41% compared to the previous year [1] Company Overview - Tianyan Pharmaceuticals is a biopharmaceutical company focused on the development of clinical products driven by its proprietary platform, specializing in novel cancer immunotherapies based on original antibodies [1] - The company utilizes a powerful platform that combines computational biology and artificial intelligence to develop new antibodies with high safety and efficacy, aiming to benefit more cancer patients [1] - The company's antibody discovery engine, known as the "Dynamic Precision Library," is advancing the development of its product pipeline, with the goal of creating potentially innovative or best-in-class products globally [1]

Core Viewpoint - The integration of artificial intelligence (AI) and biomedicine is accelerating drug development and reducing costs, with a focus on the Shanghai International Computational Biology Innovation Competition set to launch in June 2025 [1]. Group 1: Competition Overview - The competition will focus on the G protein-coupled receptor family, specifically the Hydroxycarboxylic Acid Receptor 1 (HCAR1), aiming to discover drug molecules that specifically target HCAR1 using AI computational methods [2]. - HCAR1 is identified as a potential target for anti-tumor drugs, with its abnormal activation linked to various pathological processes, including tumor progression [2]. - The competition will consist of three stages: registration, preliminary rounds, and finals, with separate evaluations for small molecules (HCAR1 antagonists) and large molecules (HCAR1-specific antibodies) [3]. Group 2: Industry Development - The launch of the competition aligns with Shanghai's goal to build an internationally influential biomedicine innovation hub, creating a world-class biomedicine industry cluster [4]. - The competition aims to create an innovative closed loop from basic discovery to technology validation and application, gathering resources from universities, research institutions, and CROs [4]. - By 2025, the Shanghai Computational Biology Innovation Development Action Plan aims to establish a comprehensive computational biology research paradigm and develop a biobig data platform, fostering talent and achieving breakthroughs in various fields [4]. Group 3: Impact on Drug Development - The competition is part of the action plan to connect industry development, encouraging universities and enterprises to showcase original products in algorithms, software, and structures [5]. - Such competitions are expected to alleviate the issue of "heavy on papers, light on translation" in innovative drug development, providing a source of innovation for globally competitive original drugs [5]. - The technological outcomes and collaborative effects generated by the competition are anticipated to be key drivers for upgrading the biomedicine industry in the city [5].